Cell-Easy raised €7M from Mérieux Equity Partners, M Capital Partners and Irdi Soridec Gestion.

Cell-Easy, a Toulouse, France-based pharmaceutical laboratory specialized in the development and manufacturing of novel cell therapies, announced raising €7M ($8.5M).

The money was raised from investors including Mérieux Equity Partners, M Capital Partners and Irdi Soridec Gestion.

The proceeds will be used for accelerating the company’s growth in France and internationally, by expanding Cell-Easy management team and strengthening the company’s commercial presence in key regions.

Cell-Easy, led by CEO Pierre Monsan, is a stem cell Contract Development and Manufacturing Organization (CDMO) that provides ready-to-inject adipose-derived allogeneic stem cells for preclinical and clinical drug development.

The company operates a manufacturing unit compliant with current Good Manufacturing Practice (cGMP) regulation, inspected by French National Agency of Medicine and Health Products Safety (ANSM), which is scalable and guarantees optimal product safety and quality.

Cell-Easy intends to expand its industrial manufacturing platform, in order to respond to the growing demand in stem cells and more generally in cell therapies, coming from biotechnology and pharmaceutical companies as well as clinical research centers in hospitals and universities.